This finding suggests that SGLT-2 inhibitors may play a role in improving outcomes in this patient population.20 Although MASLD represents a distinct etiology, the observed reduction in hepatic fibrosis suggests that SGLT-2 inhibitors may have beneficial effects on the liver that could extend to patients with cirrhosis. The gene discussed is SLC5A2; the disease is Cirrhosis.